RU2015143106A - Терапия злокачественных опухолей - Google Patents
Терапия злокачественных опухолей Download PDFInfo
- Publication number
- RU2015143106A RU2015143106A RU2015143106A RU2015143106A RU2015143106A RU 2015143106 A RU2015143106 A RU 2015143106A RU 2015143106 A RU2015143106 A RU 2015143106A RU 2015143106 A RU2015143106 A RU 2015143106A RU 2015143106 A RU2015143106 A RU 2015143106A
- Authority
- RU
- Russia
- Prior art keywords
- mycobacterium
- malignant tumor
- paragraphs
- tumor
- providing
- Prior art date
Links
- 201000011510 cancer Diseases 0.000 title claims 21
- 238000002560 therapeutic procedure Methods 0.000 title claims 2
- 241000186359 Mycobacterium Species 0.000 claims 37
- 238000000034 method Methods 0.000 claims 19
- 206010028980 Neoplasm Diseases 0.000 claims 17
- 229940124302 mTOR inhibitor Drugs 0.000 claims 11
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 claims 11
- 208000035269 cancer or benign tumor Diseases 0.000 claims 8
- 230000001717 pathogenic effect Effects 0.000 claims 8
- 210000004027 cell Anatomy 0.000 claims 5
- 206010027476 Metastases Diseases 0.000 claims 4
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims 4
- 241000187918 Mycobacterium obuense Species 0.000 claims 3
- 238000002347 injection Methods 0.000 claims 3
- 239000007924 injection Substances 0.000 claims 3
- 230000009401 metastasis Effects 0.000 claims 3
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims 3
- 229960002930 sirolimus Drugs 0.000 claims 3
- BUROJSBIWGDYCN-GAUTUEMISA-N AP 23573 Chemical compound C1C[C@@H](OP(C)(C)=O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 BUROJSBIWGDYCN-GAUTUEMISA-N 0.000 claims 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims 2
- 201000009030 Carcinoma Diseases 0.000 claims 2
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 2
- 241000187473 Mycobacterium aurum Species 0.000 claims 2
- 241001494992 Mycobacterium indicus pranii Species 0.000 claims 2
- 241001532512 Mycobacterium parafortuitum Species 0.000 claims 2
- 241000187481 Mycobacterium phlei Species 0.000 claims 2
- 241000187644 Mycobacterium vaccae Species 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000021712 Soft tissue sarcoma Diseases 0.000 claims 2
- 229960005167 everolimus Drugs 0.000 claims 2
- 201000010536 head and neck cancer Diseases 0.000 claims 2
- 238000010438 heat treatment Methods 0.000 claims 2
- 238000007912 intraperitoneal administration Methods 0.000 claims 2
- 238000001990 intravenous administration Methods 0.000 claims 2
- 201000010982 kidney cancer Diseases 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 210000004185 liver Anatomy 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000029565 malignant colon neoplasm Diseases 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 230000001394 metastastic effect Effects 0.000 claims 2
- 206010061289 metastatic neoplasm Diseases 0.000 claims 2
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 claims 2
- 229960003105 metformin Drugs 0.000 claims 2
- 210000000496 pancreas Anatomy 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 230000002685 pulmonary effect Effects 0.000 claims 2
- 229960001302 ridaforolimus Drugs 0.000 claims 2
- 238000007920 subcutaneous administration Methods 0.000 claims 2
- 230000004083 survival effect Effects 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 210000003679 cervix uteri Anatomy 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 230000002496 gastric effect Effects 0.000 claims 1
- 210000003494 hepatocyte Anatomy 0.000 claims 1
- 230000002601 intratumoral effect Effects 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 201000004477 skin sarcoma Diseases 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- 229960000235 temsirolimus Drugs 0.000 claims 1
- QFJCIRLUMZQUOT-UHFFFAOYSA-N temsirolimus Natural products C1CC(O)C(OC)CC1CC(C)C1OC(=O)C2CCCCN2C(=O)C(=O)C(O)(O2)C(C)CCC2CC(OC)C(C)=CC=CC=CC(C)CC(C)C(=O)C(OC)C(O)C(C)=CC(C)C(=O)C1 QFJCIRLUMZQUOT-UHFFFAOYSA-N 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 210000001685 thyroid gland Anatomy 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/542—Mucosal route oral/gastrointestinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/544—Mucosal route to the airways
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Dermatology (AREA)
- Otolaryngology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1308325.8 | 2013-05-09 | ||
| GBGB1308325.8A GB201308325D0 (en) | 2013-05-09 | 2013-05-09 | Cancer Therapy |
| PCT/GB2014/051421 WO2014181121A1 (en) | 2013-05-09 | 2014-05-09 | Cancer therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2015143106A true RU2015143106A (ru) | 2017-06-15 |
Family
ID=48672024
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2015143106A RU2015143106A (ru) | 2013-05-09 | 2014-05-09 | Терапия злокачественных опухолей |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20160074494A1 (https=) |
| EP (1) | EP2994148B8 (https=) |
| JP (1) | JP2016520057A (https=) |
| KR (1) | KR20160022803A (https=) |
| CN (1) | CN105407901A (https=) |
| AU (1) | AU2014264434A1 (https=) |
| BR (1) | BR112015025719A2 (https=) |
| CA (1) | CA2907841A1 (https=) |
| DK (1) | DK2994148T3 (https=) |
| ES (1) | ES2618050T3 (https=) |
| GB (1) | GB201308325D0 (https=) |
| HU (1) | HUE031783T2 (https=) |
| MX (1) | MX2015014344A (https=) |
| PL (1) | PL2994148T3 (https=) |
| RU (1) | RU2015143106A (https=) |
| SG (1) | SG11201507847UA (https=) |
| SI (1) | SI2994148T1 (https=) |
| WO (1) | WO2014181121A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201120779D0 (en) | 2011-12-02 | 2012-01-11 | Immodulon Therapeutics Ltd | Cancer therapy |
| GB201322725D0 (en) | 2013-12-20 | 2014-02-05 | Immodulon Therapeutics Ltd | Cancer therapy |
| KR20180015269A (ko) * | 2015-06-24 | 2018-02-12 | 이모듈런 테라퓨틱스 리미티드 | 암 치료에 사용하기 위한 체크포인트 저해제와 마이코박테리움 전체 세포 |
| KR101832892B1 (ko) * | 2015-08-24 | 2018-02-27 | 가톨릭대학교 산학협력단 | 면역억제제로 유발되는 미토콘드리아 질환 및 면역 질환의 예방 또는 치료를 위한 메트포민을 포함하는 조성물 |
| GB201601248D0 (en) * | 2016-01-22 | 2016-03-09 | Immodulon Therapeutics Ltd | Cancer therapy |
| GB201608806D0 (en) * | 2016-05-19 | 2016-07-06 | Immodulon Therapeutics Ltd | Method |
| WO2018112360A1 (en) * | 2016-12-16 | 2018-06-21 | Evelo Biosciences, Inc. | Combination therapies for treating cancer |
| WO2018112364A1 (en) * | 2016-12-16 | 2018-06-21 | Evelo Biosciences, Inc. | Combination therapies for treating melanoma |
| WO2019075452A1 (en) * | 2017-10-13 | 2019-04-18 | Evelo Biosciences, Inc. | IDENTIFICATION OF BACTERIA FOR CANCER THERAPY |
| CN109329204B (zh) * | 2018-10-12 | 2021-02-12 | 中国医学科学院北京协和医院 | 胰腺癌动物模型的构建方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU4281200A (en) | 1999-04-23 | 2000-11-10 | Qlt Inc. | Immuno-adjuvant pdt treatment of metastatic tumors |
| US20020022032A1 (en) | 1999-04-23 | 2002-02-21 | Curry Patrick Mark | Immuno-adjuvant PDT treatment of metastatic tumors |
| WO2006109300A1 (en) | 2005-04-14 | 2006-10-19 | Hadasit Medical Research Services & Development Ltd. | Pre-transplantation treatment of donor cells to control graft versus host disease (gvhd) in transplant recipients |
| WO2008110491A2 (en) * | 2007-03-09 | 2008-09-18 | University Of Basel | Chemotherapy of neoplastic diseases using combinations of rapamycin and compounds modulating mtor pathway alone or in combination with heat |
| EP2085466A1 (en) * | 2008-01-29 | 2009-08-05 | AEterna Zentaris GmbH | Non-pathogenic and/or attenuated bacteria capable of inducing apoptosis in macrophages, process of manufacturing and uses thereof |
| AU2010270030B2 (en) * | 2009-07-08 | 2015-12-24 | Baltic Bio Ab | 1, 2, 4-thiazolidin-3-one derivatives and their use in the treatment of cancer |
| GB201120779D0 (en) * | 2011-12-02 | 2012-01-11 | Immodulon Therapeutics Ltd | Cancer therapy |
| US8617520B2 (en) * | 2012-02-15 | 2013-12-31 | Immodulon Therapeutics Limited | Cancer therapy |
-
2013
- 2013-05-09 GB GBGB1308325.8A patent/GB201308325D0/en not_active Ceased
-
2014
- 2014-05-09 AU AU2014264434A patent/AU2014264434A1/en not_active Abandoned
- 2014-05-09 PL PL14723864T patent/PL2994148T3/pl unknown
- 2014-05-09 DK DK14723864.6T patent/DK2994148T3/en active
- 2014-05-09 SI SI201430160A patent/SI2994148T1/sl unknown
- 2014-05-09 JP JP2016512418A patent/JP2016520057A/ja active Pending
- 2014-05-09 CN CN201480020906.8A patent/CN105407901A/zh active Pending
- 2014-05-09 RU RU2015143106A patent/RU2015143106A/ru not_active Application Discontinuation
- 2014-05-09 BR BR112015025719A patent/BR112015025719A2/pt not_active IP Right Cessation
- 2014-05-09 ES ES14723864.6T patent/ES2618050T3/es active Active
- 2014-05-09 US US14/785,579 patent/US20160074494A1/en not_active Abandoned
- 2014-05-09 KR KR1020157028621A patent/KR20160022803A/ko not_active Withdrawn
- 2014-05-09 MX MX2015014344A patent/MX2015014344A/es unknown
- 2014-05-09 CA CA2907841A patent/CA2907841A1/en not_active Abandoned
- 2014-05-09 WO PCT/GB2014/051421 patent/WO2014181121A1/en not_active Ceased
- 2014-05-09 HU HUE14723864A patent/HUE031783T2/en unknown
- 2014-05-09 SG SG11201507847UA patent/SG11201507847UA/en unknown
- 2014-05-09 EP EP14723864.6A patent/EP2994148B8/en not_active Not-in-force
Also Published As
| Publication number | Publication date |
|---|---|
| EP2994148A1 (en) | 2016-03-16 |
| EP2994148B1 (en) | 2017-02-01 |
| JP2016520057A (ja) | 2016-07-11 |
| AU2014264434A1 (en) | 2015-10-08 |
| ES2618050T3 (es) | 2017-06-20 |
| WO2014181121A1 (en) | 2014-11-13 |
| CN105407901A (zh) | 2016-03-16 |
| EP2994148B8 (en) | 2017-08-30 |
| DK2994148T3 (en) | 2017-03-13 |
| BR112015025719A2 (pt) | 2017-07-18 |
| GB201308325D0 (en) | 2013-06-19 |
| US20160074494A1 (en) | 2016-03-17 |
| MX2015014344A (es) | 2016-06-21 |
| PL2994148T3 (pl) | 2017-07-31 |
| SG11201507847UA (en) | 2015-11-27 |
| HUE031783T2 (en) | 2017-07-28 |
| SI2994148T1 (sl) | 2017-07-31 |
| KR20160022803A (ko) | 2016-03-02 |
| CA2907841A1 (en) | 2014-11-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2015143106A (ru) | Терапия злокачественных опухолей | |
| JP2016520057A5 (https=) | ||
| RU2016123370A (ru) | Ингибитор контрольных точек и цельноклеточная микробактерия для использования при лечении онкологического заболевания | |
| NZ580009A (en) | Combination therapies comprising quinoxaline inhibitors of pi3k-alpha for use in the treatment of cancer | |
| TW201613589A (en) | Combination methods for treating cancers | |
| JP2016528162A5 (https=) | ||
| CN112888458A (zh) | Cldn18的抗体和化疗药物的联合治疗 | |
| PH12016502354A1 (en) | Pharmaceutical composition | |
| RU2016118753A (ru) | Производные пиридилкетона, способ их получения и их фармацевтическое применение | |
| RU2017115771A (ru) | 17a,21-диэфиры кортексолона для применения в лечении опухолей | |
| RU2013134359A (ru) | Комбинированная терапия с применением индуктора и ингибитора аутофагии для лечения новообразований | |
| RU2015152785A (ru) | Лечение злокачественной опухоли налтрексоном | |
| RU2016147654A (ru) | Соединения для лечения рака | |
| RU2018102547A (ru) | Ингибитор контрольных точек и целые клетки микобактерий для применения в терапии рака | |
| PH12021552973A1 (en) | Methods of treating urinary system cancers | |
| RU2015156221A (ru) | Фармацевтические комбинация ингибитора pi3k и средства, дестабилизирующего микротрубочки | |
| IL276235B1 (en) | Use of Minfrain to reduce tumor growth | |
| MX2021015802A (es) | Terapia de combinacion. | |
| Huang et al. | Safety of lienal polypeptide injection combined with chemotherapy in treating patients with advanced cancer | |
| JP2011500841A5 (https=) | ||
| JP2013506626A5 (https=) | ||
| ME02725B (me) | Inhibitori proteazoma za lećenje kancera | |
| JP2015516464A5 (https=) | ||
| NZ760040A (en) | Methods of treating brain tumors using combination therapy | |
| Dutcher | High-dose interleukin-2 therapy for metastatic renal cell carcinoma and metastatic melanoma: still the standard |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20180314 |